# Council Memo — 2026-10-26

*This memo is a structured synthesis of your own agents' analysis of data fetched this
session. It is not licensed investment advice. Every number comes from this sweep's
snapshot (`20261026T061206.json`), candidates CSV (`20261026T061214-candidates.csv`),
`candidate_history.csv`, the calendar file, or the four lens outputs relayed this
session. Anything else is labelled: carried from a prior file, or this memo's own
arithmetic.*

---

## What leads this memo

**1. ABB.ST: the SELL is decided fresh this week, and it is a SELL (conviction 4, Low
confidence). The condition the 2026-10-12 Chairman set was never met.**
- That condition was a test on *confirmed, reported Q3 numbers*. No file this session
  confirms that the snapshot holds post-10-20 Q3 data. The calendar returned 10-20 as
  ABB's "next" date, which is already past. Both `valuation` and `thesis-review` say so.
  The retest is blocked on data, not on analysis.
- On the best numbers available, **neither leg-set of the pre-committed test passes
  cleanly**:
  - *Retire* needs operating margin >16.9% **and** forward P/E clearly below trailing.
    The margin passes (18.67%). The forward gap fails: 31.01 vs 31.51, about 1.6%.
  - *Revive* needs FCF/revenue of ~4–5% **and** a flat forward gap. The gap is flat, but
    FCF/revenue is **5.53%**. That is outside the band, and it moved *toward* retirement
    (4.4% last week).
- So `valuation`'s "REVIVED" is a stronger reading than the numbers support.
  `thesis-review`'s "leans revive" is closer. I name the disagreement in #1 rather than
  pick a lens.
- **The SELL rests on a fresh judgement, not on the test.** ABB is still the most
  expensive name held (31.5x trailing, 31.0x forward). `thesis-review` answers "would I
  buy it today?" NO for a fourth time. It sits in the one ACT-rated sector, and the
  rotation destination has its own BUY. See #1.

**2. Process note (S27): the launch prompt again misstated two settled facts and, by
the orchestrator's report, again left out `scout.py`. The orchestrator ran scout anyway.**
- The Handelsbanken wrapper question is closed (2026-07-07/08-03).
- `investor_profile.json.reference_targets` is populated, not empty. It is stale against
  `portfolio.json.targets`, which is S35. I verified this directly this session: 85/10/0/5,
  with no `gold_pct`.
- I cannot read the scheduled prompt itself, so the recurrence rests on the
  orchestrator's report. By OPEN_ITEMS.md's count chain this is the **10th occurrence**.
  It is the second in which a mandatory stage was left out. Both were caught before any
  wrong action.
- One S27 sub-finding **did** get fixed. This snapshot contains a Bitcoin spot price
  (71,335 EUR), the first in three sweeps. BTC0E.AS still has no price of its own (§6,
  D-c).

---

## 1. Position report

`scripts/position_report.py` output, unchanged:

| Position | Price | Δ vs prev snapshot | Δ vs cost | 52w range | Value (SEK) | Source |
|---|---|---|---|---|---|---|
| Handelsbanken A (stock) | 147.70 | -2.4% | +14.3% | 75% | 147.70 | fetched |
| Investor A (stock) | 403.30 | -0.6% | +39.0% | 87% | 2,016.50 | fetched |
| Volvo B | 311.20 | -2.7% | -15.3% | 47% | 4,045.60 | fetched |
| Atlas Copco B | 156.80 | -10.6% | -13.5% | 43% | 4,233.60 | fetched |
| AstraZeneca | 1,713.50 | +2.3% | +11.4% | 54% | 13,708.00 | fetched |
| Xetra-Gold (physically-backed gold ETC, ISIN DE000A0S9GB0) | no data | no data | no data | - | 5,689.22 | FETCH FAILED |
| Alfa Laval | 541.00 | -5.3% | -5.8% | 68% | 4,869.00 | fetched |
| ABB | 825.60 | -9.8% | -12.8% | 45% | 3,302.40 | fetched |
| Avanza Auto 3 (fund) | no data | no data | +65.2% | - | 16,191.00 | book value |
| Avanza Global (fund) | no data | no data | +0.0% | - | 119,999.00 | book value |
| Valour Bitcoin Zero SEK (certificate, ISIN CH0585378661) | no data | no data | no data | - | 11,031.00 | FETCH FAILED |
| ETH (self-custody wallet) | 23,011.02 | -5.2% | no data | - | 11,548.08 | fetched (CoinGecko, converted via sek_per_eur) |

Crypto context (CoinGecko): bitcoin 71,335.00 EUR (7d −3.1%, 30d −4.5%, −33.7% vs ATH);
ethereum 2,065.64 EUR (−4.7% vs prev snapshot, 30d −13.6%, −51.2% vs ATH).

**What moved, and whether it matters:**
- **The four industrials lost ~1,245 SEK between them this week** (17,696.10 → 16,450.60,
  my arithmetic; the prior figure is from the 10-19 position report). ATCO −10.6%, ABB
  −9.8%, ALFA −5.3% and VOLV −2.7% all fell during their own print week.
  - **No thesis is contradicted by the price.** ATCO's break condition (ttm revenue
    turning negative) moved the other way: revenue is now **+15.1%**, from the +9.1%
    that had been byte-identical since August. Volvo's ttm revenue went +2.7% → **+8.0%**.
    Both fields visibly rolled forward this week. That matters for reading ABB (#1).
- **AZN +2.3%**, in line with the defensive bid elsewhere in the file (PEP +8.1%, JNJ
  +5.7%, KO at 100% of range, all from `candidate_history.csv`). It reports 10-30.
- **ETH −5.2%** shrinks the crypto sleeve (§6, D-c).
- **Not repriced:** the index funds are at book value and gold/BTC at stale marks. That
  is 152,910.22 SEK, **68.4%** of the ~223,644 SEK total (my arithmetic), unrepriced
  again.

---

## 2. Scout health

```
Universe: 624 | Fetched: 621 (cache 0, new 625, failed 4) | Ranked: 613 | Candidates: 73 (holdings 9, watchlist 30, new 34) | Focus: 24 | Screened: 73 | Passed: 37 | Missing: 17 | Failed: 19 | Status: VALID
```

**Reading: VALID. The funnel ran, and nothing upstream needs distrusting before §3.**
The universe is 28 days old and due for refresh next sweep.

**"New" is not "first seen" (fourth explicit catch).** 34 rows carry `source=new`. I
checked them against all ten runs in `candidate_history.csv`.
- **One is genuinely first-seen: WIHL.ST** (rank 9). It is absent from every prior run
  (08-25 through 10-19).
- **Two are returnees:** CATE.ST (last seen 10-05, previously ranks 12–23) and SMCI (last
  seen 10-12).
- **Four left since 10-19:** BALD-B.ST, CME, EXE, PLTR.

**The frozen head:**
- **APP has been rank 1 in 10 of 10 runs. NVDA has been top-10 in 10 of 10.**
- **VICI fell 9 → 13, its first exit from the top 10 in ten runs.** The price rose (23.46
  → 24.02), which lowers its contrarian score. That is mechanical. Rank is not evidence
  here (S33).

**Suspect values, two corrections to the relayed scout notes:**
- **INVE-A.ST `revenue_growth` −60.8% is not new.** The 2026-10-19 memo already recorded
  it (§2 of that memo, alongside a ttm "revenue" of 282B SEK against FY2025's 64.8B). It is
  the **second** sweep, and the CSV's `suspect` column for INVE-A.ST is still empty.
- **The root cause is contested.** `valuation` attributes it to the USD/SEK mislabelling
  (S32). Last week's evidence (a ttm "revenue" ~4x fiscal revenue) fits the
  Industrivärden pattern better: a holding company's investment gains counted as
  revenue. That is a hypothesis. Either way the field is withheld below and never
  reasoned from.
- **Still unflagged:** TSM `fcf_yield_pct` **55.43%**, and AZN.ST/ABB.ST `fcf_yield_pct`
  0.2/0.14 (S32 unit errors). They are not used below except FX-corrected.

---

## 3. Top opportunities

### 3a. The seven voices (independent passes)

Each voice triaged all 73 rows on its own columns before drafting. A pick pulled in from
outside `focus=Y`, or argued against its screen flag, is labelled as such.

#### Voice 1 — Fundamental / Quality

*Triage (`z_quality`):* APP 2.557, NVDA 2.543, SNDK 2.511, MU 2.507, MA 2.254, V 1.959,
TPL 1.805, AZA.ST 1.755, LLY 1.747, MO 1.552, TSM 1.517, BURE.ST 1.390, GOOGL 1.369.
*Moat, management and capital allocation are qualitative here; no fetched field measures
them.*

- **BUY V, 8.**
  - Why: ROIC 41.5%, ROE 61.2%, margins 50.8/66.1, net debt/EBITDA 0.32, revenue +14.4%
    on a 10.9% CAGR. Every field is unchanged.
  - The +3.6% week (399.75 → 414.34) to 100% of range is Valuation's objection, not mine.
  - Risk: interchange-fee regulation (qualitative).
  - Invalidated by: ROIC below 30%.
- **BUY MA, 7 (pulled in against its FAIL).**
  - Why the FAIL misleads: D/E 439.58 comes from buyback-driven negative equity, while
    net debt/EBITDA is 0.59.
  - Underneath: ROIC 56.1%, margins 46.3/61.1, revenue +14.1% on a 13.8% CAGR.
  - Invalidated by: net debt/EBITDA above 2.0.
- **BUY NVDA, 7.**
  - Why: ROIC 59.2%, ROE 117.2%, margins 63.7/66.2, net cash (−0.12).
  - Held at 7: FCF yield 0.82% against an earnings yield of 3.75% (1/26.67). Only ~22% of
    earnings reach free cash.
  - Invalidated by: FCF yield still below 1% after the next print. Its date is not in
    this sweep's calendar.
- **BUY ATCO-B.ST (holding), 7 (up from 6).**
  - Why: the break-condition test I named last week has now been run, and it passed. Ttm
    revenue is **+15.1%**, the first change in that field since August.
  - Underneath: ROIC 38.5%, op margin 20.8%, net debt/EBITDA 0.3, FCF yield 3.4% (SEK
    over SEK, clean).
  - The −10.6% week bought the same business cheaper.
  - Invalidated by: ttm revenue turning negative.
- **ABB.ST: SELL withdrawn.**
  - My case was the thinnest cash conversion held, and my invalidation was FCF/revenue
    above ~8%. It has moved 4.4% → **5.53%** in the print week, with op margin at 18.67%,
    ROIC 23.3% and net debt/EBITDA 0.32.
  - That is not 8%. But I will not sell a business on quality grounds while both of its
    quality fields move toward my own invalidation.
- **Declined:**
  - **APP.** ROE 203.7% on D/E 111.13 is leverage-inflated.
  - **MU/SNDK.** Peak-cycle margins (80.7/78.5%) and suspect growth; prices −8.0%/−9.6%
    this week.
  - **AZA.ST.** Forward 26.86 vs trailing 18.97 implies ~−29% EPS; price −6.4%.
  - **TPL.** Its forward multiple is not credible.

#### Voice 2 — Valuation

*Triage (`z_value`):* CHTR 1.896, CMCSA 1.823, FIS 1.769, ALL 1.672, DOM.ST 1.636,
CORE-B.ST 1.617, EG 1.597, GM 1.541, FISV 1.502, BURE.ST 1.437, MEKO.ST 1.365, INDU-C.ST
1.257, DIOS.ST 1.198, INVE-A.ST 1.077, FSLR 1.060, EIX 1.056.
*Named gap: no EV/EBITDA or EV/EBIT. Where I lean on net debt/EBITDA, I say so.*

- **BUY VICI, 7.**
  - Why: 9.25x trailing, 7.95x forward, 7.74% dividend, 67.5% net margin, revenue +5.7%
    on a 15.5% CAGR, PASS. Ten runs, no fetched field deteriorated.
  - Price +2.4% to 18% of range: the margin of safety is a little thinner, nothing broke.
  - Approximation: net debt/EBITDA 4.82 is heavy. I quote no enterprise multiple.
  - Missing: FFO/AFFO and lease coverage. PEG is null this run.
  - Invalidated by: a dividend cut, or net debt/EBITDA above 6.
- **BUY NVDA, 7.**
  - Why: forward 13.26x against trailing 26.67x on +105.9% revenue. The forward multiple
    fell again (13.45 → 13.26) as the price slipped 2.3%.
  - PEG 0.26 is not relied on.
  - Invalidated by: forward rising above trailing.
- **BUY AZN.ST (holding), 6.**
  - Why: PEG 1.21, with the lens's FX-corrected P/S/P/B not stretched for large-cap
    pharma.
  - Missing: `forward_pe` in **10 of 10** runs (S21).
  - Invalidated by: PEG above 1.6.
- **BUY FSLR, 5 (up from 4; rank 42, second run).**
  - Why: forward 7.32x vs trailing 10.60x, FCF yield 8.65% against a 9.43% earnings yield
    (~92% conversion), net cash (−0.64), D/E 1.88. Now 2% of range, from 7%.
  - Second consecutive run on these fields.
- **BUY VOLV-B.ST (holding), 5.**
  - Why: PEG 0.89, forward 12.36 is 29% below trailing 17.45, and ttm revenue turned to
    +8.0%.
  - Risk: leverage (D/E 140.9, net debt/EBITDA 3.69). That is the watch item, not the
    multiple.
- **SELL ABB.ST, 4.**
  - Why: 31.51x trailing and 31.01x forward are the richest pair held, and a flat gap
    means flat expected EPS on 14.3% revenue growth.
  - The multiple compressed (35.3x → 31.5x) only because the price fell. My own
    concession: PEG 1.2 is now the lowest of the Swedish-listed industrials except Volvo.
- **ATCO-B.ST: SELL withdrawn.** Trailing fell 32.4x → 27.65x and PEG 2.15 → 1.91. Not
  cheap, but no longer the sell case.
- **Cheap for a reason, not picks:**
  - **CHTR, CMCSA.** Revenue −1.7%/−6.1%.
  - **ALL.** Forward 9.01 vs 5.07 implies earnings nearly halving.
  - **EG.** Revenue −11.3% at 98% of range.
  - **FIS.** A +29.1% ttm against a −9.8% CAGR is a base effect.
  - **WIHL.ST, CATE.ST, DIOS.ST.** Net debt/EBITDA 10.78/10.85/9.88. A single-digit P/E
    on that leverage is the leverage, priced.
  - **SMCI.** FCF yield −38.1%.
  - **TPL.** A 4.6x forward against 43.1x trailing is not a usable estimate.

#### Voice 3 — Growth / Opportunity

*Triage (`z_growth`):* NVDA 1.923, SMCI 1.772, AVGO 1.763, APO 1.731, BE 1.679, AXON
1.581, DASH 1.542, FIX 1.521, MU 1.488, LLY 1.466, APP 1.447, AMD 1.419.
*Forward below trailing (cleanest):* NVDA 13.26/26.67, APP 12.68/20.00, FIX 19.05/25.07,
FSLR 7.32/10.60, VOLV-B.ST 12.36/17.45, META 18.33/21.92.
*Not trusted:* MU 4.24/11.81 and SNDK 4.65/16.78 (suspect growth), TPL, GM, MEKO.ST,
APO, AMD, AXON, DASH, BE (gaps of 3–8x).
*Named gaps: no TAM, earnings-revision or market-share data.*

- **BUY NVDA, 8.**
  - Why: revenue +105.9% on a 100.0% CAGR, forward at half of trailing, no suspect flag.
  - Risk: a hyperscaler capex pause (qualitative).
  - Invalidated by: growth below 40%, or forward above trailing.
- **BUY FIX, 7 (up from 6; rank 32, pulled in).**
  - Why: revenue +53.7% on a 30.0% CAGR, forward 19.05x vs 25.07x, PEG 0.39, ROIC 43.7%,
    net cash (−0.81). FCF yield 5.21% *exceeds* its 3.99% earnings yield.
  - The price fell **13.6%** this week (1,481.27 → 1,279.37) with no fetched field
    deteriorating. The same growth now costs a forward multiple of 19.05, down from 23.90
    (carried from the 10-19 memo).
  - Risk: beta 1.659, and margin 13.0% is thin for a contractor.
  - Invalidated by: growth below 25%.
- **BUY VOLV-B.ST (holding), 6 (up from 5).**
  - Why: ttm revenue went +2.7% → +8.0% in the print week. The forward multiple (12.36
    vs 17.45) prices a ~41% EPS rise.
  - Invalidated by: ttm revenue turning negative again.
- **BUY APP, 5.**
  - Why: +52.8% revenue at a 77.7% op margin. Forward 12.68 vs 20.00 means consensus still
    expects EPS ~+58%.
  - The price (−5.4% this week, now 1% of range) disagrees with the estimates, and no
    fetched field explains it (S29).
  - Its print date is not in this sweep's calendar.
- **SELL SHB-A.ST, 3.** Revenue −2.1% (improved from −3.8%), forward 13.13 above trailing
  12.74, z_growth −1.234, the worst held. Lower than last week because the decline
  narrowed.
- **ABB.ST: no SELL.** 14.3% measured growth at PEG 1.2 is not a growth-lens sell.
- **Declined:**
  - **META.** −11.9% this week (736.72 → 648.85) and no file explains it. I will not buy
    a drop I cannot attribute.
  - **SMCI.** FCF −38.1%.
  - **AVGO.** +85.5% against a 24.4% CAGR is likely an acquisition base.
  - **MU/SNDK.** Suspect growth fields.

#### Voice 4 — Defensive / Risk

*Triage (lowest `beta`):* SAAB-B.ST 0.03, ALL 0.138, BETS-B.ST 0.17, JNJ 0.206, AZN.ST
0.212, ABBV 0.228, EG 0.259, KO 0.318, TEL2-B.ST 0.34, PEP 0.364, PG 0.377, NOVO-B.CO
0.384, SEB-A.ST 0.441, MO 0.461, SHB-A.ST 0.493.

**The scenario I position for:** a hawkish surprise at the **10-27/28 FOMC**, followed by
the **11-04 Riksbank** decision.
- The fed-funds and US CPI reads are 55 days stale (3.75% vs 4.02%).
- VIX rose **16.46 → 19.03** week on week (previous vs this snapshot).
- This week tech and industrials fell while staples rose (PEP +8.1%, JNJ +5.7%, KO at
  100% of range). **The defensive trade is already partly priced.** That is why two of
  my picks are low-range names, not the obvious staples.

- **BUY AZN.ST (holding), 7.**
  - Why: beta 0.212, net debt/EBITDA 1.35, op margin 23.5%, revenue +6.4% ttm, still
    54% of range, unlike the staples.
  - Invalidated by: op margin below 20% at the 10-30 print, or a dividend cut.
- **BUY SHB-A.ST (holding), 5.**
  - Why: beta 0.493, dividend 5.34%, z_defensive 1.331 (second in the set after SWED-A.ST's
    1.335). D/E is null, which means little for a bank.
  - Risk: revenue −2.1%, and a Riksbank cut compresses margins (qualitative).
- **BUY NOVO-B.CO, 4 (pulled in, rank 43).**
  - Why: beta 0.384, net debt/EBITDA 0.55, ROIC 35.6%, margins 35.3/42.5, P/E 9.93,
    dividend 4.5%, 22% of range.
  - Risk: revenue only +2.1%, and forward 11.71 above trailing implies EPS ~−15%. This is
    stability, not growth.
- **SELL VOLV-B.ST, 4.** D/E 140.9 and net debt/EBITDA 3.69 at beta 1.0: the most
  leveraged holding, in the sector most exposed to a risk-off move after the FOMC.
- **Attacking this sweep's BUY cases:**
  - **NVDA, APP, FIX, FSLR.** Betas 2.216 / 2.557 / 1.659 / 1.794.
  - **VICI.** Net debt/EBITDA 4.82, exposed to the FOMC.
  - **WIHL/CATE/DIOS.** ~10x leverage, not investable here.
  - **SMCI.** Cash burn.
  - **ALL.** Its low beta comes with an implied earnings halving.
- **Not flagging ABB.ST.** Net debt/EBITDA 0.32 and beta 0.982 give no risk case.

#### Voice 5 — Contrarian / Risk Taker

*Triage (`pct_52w_range`):* APP 1, CORE-B.ST 2, FSLR 2, DOM.ST 4, WIHL.ST 5, CATE.ST 6,
CHTR 7, FISV 8, DIOS.ST 13, AVGO 16, FIS 17, VICI 18, AXON 18, BETS-B.ST 18, CMCSA 19,
EIX 22, NOVO-B.CO 22.

- **BUY VICI, 6.**
  - Why: the discount-rate story got its **second** confirming week. The 10-year fell
    5.10 → **4.96**, and the price rose 23.46 → 24.02 again on unchanged fundamentals.
  - Two observations, not proof. Conviction holds.
  - Invalidated by: a dividend cut, or the price falling while the 10-year falls.
- **BUY FSLR, 5.**
  - Why the pessimism looks wrong: at 2% of range the price says decline (revenue −3.7%).
    The forward multiple says EPS +45%, and FCF already converts at ~92% of earnings on a
    net-cash balance sheet.
  - The pessimism is plausibly US solar policy, which is not in any file. A net-cash
    company can wait out a policy cycle.
  - Invalidated by: forward rising above trailing, or FCF turning negative.
- **BUY APP, 4.**
  - Why: the specific disagreement is between price (1% of range, −5.4% this week) and
    estimates (forward still prices +58% EPS). That gap closes one way or the other at
    the next print.
  - Without the 52-week endpoints (S29) I cannot size the drawdown.
- **PEP retired.** It was my pick last week at 10% of range. It rose 8.1% to 32%. One
  week is not validation, but the low-range edge I bought it for is gone.
- **SELL flags: none.**
- **Declined (penalty deserved):**
  - **WIHL.ST (first-seen).** 5% of range, P/E 8.86, 4.79% yield, revenue +5.4%. But
    net debt/EBITDA 10.78, and forward 11.07 above trailing implies EPS −20%. The
    pessimism is the Swedish rate path. The 11-04 Riksbank decision is the observable
    that would make me wrong.
  - **CATE.ST, DIOS.ST, CORE-B.ST, DOM.ST.** The same leverage story, or negative margins.
  - **CHTR/CMCSA.** The fundamentals agree with the price.

#### Voice 6 — Macro / Regime

*Regime (from `macro-regime`): TRANSITIONAL.* Week-on-week vs the previous snapshot:
- **Rates:** 10y 5.10 → 4.96, 2y 4.77 → 4.65, spread 0.33 → 0.31.
- **Volatility:** VIX 16.46 → 19.03.
- **Crypto sentiment:** Fear & Greed 59 (Greed) → 50 (Neutral).
- **Dollar:** DXY 121.60 → 121.40, SEK/USD 10.0039 → 9.9189 (the krona firmed ~0.85%).
- **Stale inputs:** fed funds and US CPI are still dated 09-01.

*Named gap: no commodity-price and no credit-spread data.*

**A correction to the lens, stated so it is not buried:** `macro-regime` describes the
dollar as "firming". That holds against August (~9.70 SEK/USD). **Week on week, the
dollar softened.** The crypto-headwind argument therefore rests on FOMC risk and
sentiment, not on a dollar move this week.

- **BUY AZN.ST (holding), 6.** Low beta, low rate-sensitivity, USD-reporting: the profile
  this regime rewards.
- **BUY NOVO-B.CO, 4 (pulled in).** Beta 0.384, DKK (EUR-pegged), 22% of range: the same
  profile, not yet bid up.
- **Only two picks, and why:** the regime rewards low-beta defensives with pricing power.
  Most of those in the set already sit at 86–100% of range (KO 100, MO 96, PG 91, JNJ 86).
  The regime trade is in their prices.
- **Explicit regime calls (downgrades stated, not hidden):**
  - **Crypto: no adds.** FOMC inside 48 hours, ETH −13.6% over 30 days, sentiment not yet
    at Fear. I side with the lens's contrarian warning. This is not a trim signal (D-c).
  - **Swedish industrials (ABB, ATCO, ALFA, VOLV):** additive risk only, not a thesis
    break.
  - **Swedish property (WIHL/CATE/DIOS):** binary on 11-04. Real policy rate +0.65pp
    (1.75% vs CPI 1.1%) leaves little room.
  - **SHB:** ambiguous. A cut helps credit and hurts margins.
  - **NVDA/APP/FIX:** a falling 10-year *helps* duration this week. The businesses are
    unaffected.
- **SELL flags on macro alone: none.**

#### Voice 7 — Copycat / Smart Money

**Coverage first.**
- **US:** SEC EDGAR returned 403 again (the CIK mapping), so there is **zero US insider
  data**.
- **Sweden:** Finansinspektionen covered the same 7 issuers, holdings only. **It is
  fresh this sweep for the first time in five weeks.**
- No candidate issuer was pulled (WIHL.ST, CATE.ST, DIOS.ST, AZA.ST).
- **Institutions:** `MISSING: institutional ownership not fetched`.

**Cleaning applied before reading:**
- Handelsbanken's list includes a Philip Nordfeldt purchase of **Avtech Sweden AB**
  shares. That is a different issuer, discarded.
- Dan Lindwall (SHB) appears twice ("History" and "Revised"), and so does Marcus Hvied
  (ATCO). Each is counted once.
- Volvo Car AB rows are discarded (a different company from AB Volvo).

- **BUY SHB-A.ST, 7.** The strongest smart-money read in this system's history.
  - **Four separate insiders bought in three days, 21–23 Oct, at three levels:**
    - CEO Michael Green: 10,000 @ 147.40
    - CFO Mårten Bjurman: 4,189 @ 147.70
    - Deputy CEO Dan Lindwall: 5,000 @ 149.00
    - Board member Louise Lindh: 30,000 @ 147.70, through a closely associated party
  - That is ~7.27M SEK (my arithmetic), at prices that bracket today's 147.70.
  - It lands **on top of** Chairman Pär Boman's 26 Aug cluster: ~291.8k shares across
    the four rows shown (~42.7M SEK, my arithmetic).
  - Context: these trades fall in the first open window after the report. Timing is
    routine; breadth and size are not.
  - Invalidated by: any disposal by these four, or the next print extending the revenue
    decline.
- **BUY ATCO-B.ST, 5.**
  - Who bought:
    - Deputy CEO Håkan Andersson: 5,000 A @ 181.82 (22 Oct)
    - Board member Johan Forssell, through a closely associated party: 10,000 B @ 158.65
      (23 Oct). The identity of that party is not in the data.
    - Marcus Hvied: 2,000 B (22 Oct). The price is ambiguous (158.13 vs a revised
      185.13).
  - They bought into a −10.6% week.
  - This contrasts with July's option-exercise-and-sell rows (Elmin, Hägg Liljedal),
    which were compensation.
- **BUY AZN.ST, 4 (down from 5).** CEO Soriot 60,000 @ 121.02 GBP and Chairman Demare
  2,500 @ 121.21 GBP on 14/09. Six weeks old, nothing since. The CFO's 0.00-price rows are
  vestings.
- **Reads that are not calls:**
  - **INVE-A.ST: the relayed "fresh buying" overstates it.**
    - Daniel Nodhäll bought 37,500 A shares and sold 20,284 B shares on 19–20 Oct, all at
      407.50–415.20. That is mostly a share-class switch, net +17,216 shares (my
      arithmetic).
    - Thomas Kidane bought 1,250 B @ 410.25 (23 Oct).
    - Modest net buying from two people. Not a cluster, and no call (it was BUY 4 last
      week).
  - **ALFA.ST.** Nothing since CFO Ekström's 1,000 @ 547.49 on 11/09. Today's 541.00 is
    just below it.
  - **ABB.ST.** Disposals only: Terwiesch 18,799/10,000/20,000 and Meline 2,456, between
    29/07 and 13/08. **Nothing in ten weeks.** Stale in both directions, so no SELL from
    me.
  - **VOLV-B.ST.** Board member Helena Stjernholm (closely associated) bought exactly
    1,300,000 shares across seven rows on 27/07 at ~359–361. Today's 311.20 is ~13.7%
    below that. Nothing since.
- **SELL flags: none.**

---

### 3b. Chairman's Top 5

Mechanical rank carries no evidential weight below (S33). It is reported for persistence
only.

#### #1 OPPORTUNITY: ABB.ST — ABB

**CATEGORY:** holding

**RANK HISTORY:** 65 now; 65 (10-19). **0 of 10 runs in the top 10.**

**VOICES IN FAVOR (of selling):**
- Valuation, 4: 31.5x/31.0x is the richest pair held, with flat expected EPS.
- Outside the voices: `thesis-review` (BROKEN; would-buy NO, fourth re-test) and
  `valuation` lens ("REVIVED").

**VOICES AGAINST / CAUTIOUS:**
- Fundamental: *withdrew* its SELL, since FCF/revenue moved 4.4% → 5.53%.
- Growth: no sell at 14.3% growth and PEG 1.2.
- Defensive: no risk case.
- Copycat: insider selling is ten weeks stale.
- Macro: additive industrial risk only.

**STRONGEST CASE FOR (selling):** `thesis-review`'s. Four independent "would I buy it
today?" re-tests return NO. The multiple compressed only because the price fell
(35.3x → 31.5x), not because expected earnings rose: the forward/trailing gap is ~1.6%.
At 31x, ABB is the most expensive line in the one ACT-rated sector.

**STRONGEST CASE AGAINST:** Fundamental's.
- In the very week of the print, both measurable business fields moved toward the
  *retire* side: op margin 18.67% and FCF/revenue 5.53%.
- After a −9.8% week, the SELL now rests on a single estimate field (forward P/E). This
  system has twice found estimate fields on this name unreliable (S32 history).

**KEY DISAGREEMENT:** what the pre-committed test returns.
- **Valuation lens:** "REVIVED", reading 5.53% as inside "~4–5%".
- **Thesis-review:** "leans revive; FCF just outside the band; data stale".
- **My reading of the numbers:** neither condition set is cleanly met. Retire fails on
  the forward gap; revive fails narrowly on FCF.
- **On freshness, I partly disagree with `thesis-review`.** ATCO's and VOLV's ttm fields
  visibly rolled forward this week (+9.1% → +15.1%, +2.7% → +8.0%), and ABB's FCF moved.
  The snapshot is *plausibly* post-print. ABB's near-identical revenue growth (14.2 →
  14.3) is the one field that argues otherwise. Plausible is not confirmed.
- So the test is inconclusive, and **the SELL is a fresh judgement**: a holding nobody
  would buy today, at the richest multiple held, in an ACT sector, with a funded
  destination. It is not a test result, and it is not the streak.

**DATA GAPS:**
- No confirmed Q3 report.
- No EV/EBITDA.
- FCF is trailing-only.
- P/S and P/B are unit-mismatched (S32).
- No next-print date.

These discount confidence heavily, which is why confidence is Low.

**CHAIRMAN CONVICTION:** 4

**WHAT WOULD CHANGE THIS:** ABB's own Q3 report (via the `pdf` skill). If it shows
FCF/revenue at or above ~8%, or guidance that pulls forward EPS clearly above trailing,
the SELL is withdrawn before execution. This sweep's retest failed for a data reason, and
it is logged that way.

**PORTFOLIO FIT** (from `portfolio`; my arithmetic labelled):
- Industrials are **50.89%** of the 32,322.8 SEK direct sleeve (ACT); ABB is 10.22% of
  it.
- **Sell to cash:** Industrials ~45.3% (still ACT, barely), and Sweden *rises* to ~52.8%,
  because the denominator shrinks.
- **Sell and buy 13 VICI** (3,097.28 SEK): Industrials ~40.9%, Sweden ~47.7% (still ACT).
- **Sell and execute the full queue below:** Industrials ~35.1%, Sweden ~44.9%.
  Proceeds 4 × 825.60 = **3,302.40 SEK**, tax-free inside the ISK.

**FINAL CALL: SELL** — all 4 shares, proceeds to 13 VICI (#4).

**HORIZON:** Medium

#### #2 OPPORTUNITY: SHB-A.ST — Handelsbanken A

**CATEGORY:** holding

**RANK HISTORY:** 41 now; 41 (10-19). **0 of 10 in the top 10.**

**VOICES IN FAVOR:**
- Copycat, 7: four insiders at three levels in three days, ~7.27M SEK.
- Defensive, 5: beta 0.493, 5.34% yield.

**VOICES AGAINST / CAUTIOUS:**
- Growth: SELL 3 (revenue −2.1%, forward above trailing).
- Valuation: no pick (fair; PEG 18.73 unusable).
- Macro: ambiguous into 11-04.
- Yahoo's own tag: "underperform".

**STRONGEST CASE FOR:** Copycat's.
- CEO, CFO, Deputy CEO and a board member's associated party each bought independently,
  in the first window after the 10-21 report.
- They had seen the quarter the market is pricing as weak, and they bought at today's
  price.
- That follows a ~42.7M SEK Chairman cluster in August. This is breadth, not one insider
  repeating.

**STRONGEST CASE AGAINST:** Growth's. Revenue is still contracting (−2.1%), and forward
P/E 13.13 above trailing 12.74 says consensus expects EPS ~3% lower. Insiders can be
early by years. Insider clusters have **no measured predictive record in this system's
ledger**: Judgement pillar n is too small to say.

**KEY DISAGREEMENT:** insiders vs consensus, on the same post-print information. Not
reconciled. `thesis-review` also leaves it unresolved (WEAKENING, would-buy "yes but
smaller"). I side with buying *small* because the downside is cushioned (beta 0.493,
5.34% yield). That is a sizing judgement, not a resolution.

**DATA GAPS:**
- D/E null (bank).
- No NIM, credit-loss or capital-ratio data, the metrics a bank is actually judged on.
- The FI list shows the 10 most recent rows only.

Moderate discount.

**CHAIRMAN CONVICTION:** 5

**WHAT WOULD CHANGE THIS:** a disposal by any of the four buyers kills it. A next print
with revenue back to growth raises it.

**PORTFOLIO FIT** (applying `portfolio`'s figures):
- Financial Services is 6.70% of the sleeve (OK).
- Sweden is **47.37% (ACT)**. 10 shares (1,477.00 SEK) bought *alone* push Sweden to
  ~49.7%.
- Bought *after* the non-Swedish queue (VICI, NVDA), Sweden ends ~44.9% (my
  arithmetic).
- Sequencing is therefore the fit condition.

**FINAL CALL: BUY** — 10 shares, last in the queue, after VICI and NVDA. **Execution note:
no idle ISK capital is confirmed this sweep (`portfolio` did not restate ISK cash; the
last confirmed figure, 845.43 SEK, is from 2026-08-25). Funded by P3.**

**HORIZON:** Medium

#### #3 OPPORTUNITY: NVDA — Nvidia

**CATEGORY:** watchlist

**RANK HISTORY:** 2 now; 2 (10-19). **10 of 10 in the top 10.**

**VOICES IN FAVOR:**
- Growth, 8: +105.9% on a 100% CAGR.
- Valuation, 7: forward 13.26x, down again.
- Fundamental, 7: ROIC 59.2%, net cash.

**VOICES AGAINST / CAUTIOUS:**
- Defensive: beta 2.216 into the FOMC.
- Fundamental's own caveat: FCF is ~22% of earnings.

**STRONGEST CASE FOR:** Valuation's. For a second week, the price fell while the forward
multiple compressed (13.45 → 13.26). The market is paying less for unchanged measured
growth, with no suspect flag and no screen penalty.

**STRONGEST CASE AGAINST:** Fundamental's. FCF yield 0.82% vs a 3.75% earnings yield
(USD over USD, so real). Part of "cheap on forward earnings" is cheap on accruals until
cash catches up.

**KEY DISAGREEMENT:** cheapest measured growth vs unproven earnings quality. Unchanged
from last week and not reconciled. The next print is the test, and its date is not in
this sweep's calendar.

**DATA GAPS:**
- No revisions or backlog data.
- No US insider data.
- No print date.

Moderate discount.

**CHAIRMAN CONVICTION:** 6

**WHAT WOULD CHANGE THIS:** FCF yield moving toward the earnings yield raises it. Forward
P/E rising above trailing kills it.

**PORTFOLIO FIT** (from `portfolio`, verbatim): "NVDA/SNDK/MU/SMCI/FIS (Tech, US):
diversifies sector (0% today) and country (0% direct); concentrates tier (adds another
large-cap)."
- One share is 212.21 × 9.9189 = **2,104.89 SEK** (my arithmetic).

**FINAL CALL: BUY** — 1 share. **Execution note: no idle capital confirmed. Fund from P3,
after gold tranche 2 and AZN.**

**HORIZON:** Medium

#### #4 OPPORTUNITY: VICI — Vici Properties

**CATEGORY:** new candidate (`source=new`: not held, not watchlisted; in the funnel since
2026-08-25, not first-seen)

**RANK HISTORY:** 13 now; 9 (10-19). **9 of 10 runs in the top 10.** This is its first
exit, a mechanical effect of the price rising.

**VOICES IN FAVOR:**
- Valuation, 7: 7.95x forward, 7.74% yield, ten runs without deterioration.
- Contrarian, 6: a second confirming week on the discount rate.

**VOICES AGAINST / CAUTIOUS:**
- Defensive: net debt/EBITDA 4.82 into the FOMC.
- Macro: no downgrade, but the FOMC is the event.
- Copycat: no data.

**STRONGEST CASE FOR:** Valuation's. A 67.5%-margin landlord still growing revenue
(+5.7% on a 15.5% CAGR) at 7.95x forward with a 7.74% yield. Every fetched field has been
unchanged for ten weeks.

**STRONGEST CASE AGAINST:** Defensive's. The price is now moving with the 10-year. Two
weeks of a falling 10-year (5.22 → 5.10 → 4.96; the first figure carried from the 10-19
memo) lifted it. A hawkish 10-28 statement reverses that in one day, on a REIT levered
4.82x, with fed-funds and CPI inputs 55 days stale.

**KEY DISAGREEMENT:** is the rise mispricing correcting, or plain rate beta? Both readings
fit two observations. The retirement observable (10-year ≥5.5% with the price still
falling) moved further from firing. That holds conviction; it does not raise it.

**DATA GAPS:**
- No FFO, AFFO, EV/EBITDA or lease coverage.
- No US insider data.
- **No earnings date in this sweep's calendar** (holdings-only, the fourth straight
  sweep).

Heavy discount.

**CHAIRMAN CONVICTION:** 5

**WHAT WOULD CHANGE THIS:** a dividend cut kills it. The 10-year at ≥5.5% with the price
still falling retires it.

**PORTFOLIO FIT** (from `portfolio`, verbatim): "VICI (Real Estate, US, large):
diversifies sector AND country; concentrates tier. Standing ABB.ST-rotation destination
per OPEN_ITEMS — clean diversification add on this read alone."
- One correction carried from last week: the ABB → VICI swap fixes sector more than
  geography. Sweden stays ACT (~47.7%) until the rest of the queue lands.
- Price in SEK: 24.02 × 9.9189 = **238.25 SEK** (my arithmetic). 13 shares cost 3,097.28
  (within the ABB proceeds); 15 cost 3,573.78.
- Confirm it is orderable in the Avanza ISK, and check how US dividend withholding is
  treated there.

**FINAL CALL: BUY** — 13 shares from the ABB proceeds. If ABB is not sold, 15 shares from
P3. **Execution note: no idle capital is confirmed; funding depends on the ABB sale or
P3.**

**HORIZON:** Medium

#### #5 OPPORTUNITY: FIX — Comfort Systems USA

**CATEGORY:** new candidate (`source=new`; first in `candidate_history.csv` 2026-09-21,
a returnee, not first-seen)

**RANK HISTORY:** 32 now; 28 (10-19). **0 of 10 in the top 10.**

**VOICES IN FAVOR:** Growth, 7: +53.7% revenue, forward 19.05 vs 25.07, FCF above
earnings, and a −13.6% week on unchanged fields.

**VOICES AGAINST / CAUTIOUS:**
- Defensive: beta 1.659.
- Macro: a high-beta cyclical inside the FOMC window.
- Fundamental did not pick it, but its fields would pass that bar (ROIC 43.7%, net cash).
- Copycat: no data.

**STRONGEST CASE FOR:** Growth's. This is the cleanest growth-plus-cash name in the set.
FCF yield 5.21% *exceeds* its 3.99% earnings yield, the reverse of NVDA's problem, on net
cash. This week's drop compressed the forward multiple by about a fifth with no field
deteriorating.

**STRONGEST CASE AGAINST:** Defensive's. A beta-1.659 contractor that fell 13.6% in a
week, with no file explaining why, ahead of a rate decision. A drop without a cause in
the data is not automatically an opportunity.

**KEY DISAGREEMENT:** none on merit among the voices that looked. The disagreement is
fit, and it is decisive (below).

**DATA GAPS:**
- No backlog data, the metric a contractor is actually valued on.
- No insider data, no earnings date.
- Margin 13.0% is the only thin field.

**CHAIRMAN CONVICTION:** 5

**WHAT WOULD CHANGE THIS:** a third run holding the forward multiple below trailing with
FCF above earnings, *and* a funding route that does not concentrate the portfolio. In
practice, that means waiting until the Industrials share is no longer ACT.

**PORTFOLIO FIT** (applying `portfolio`'s figures; FIX was not in its focus list):
- **One share is 1,279.37 × 9.9189 = 12,689.94 SEK, about 5.7% of total capital** (my
  arithmetic). That one share alone would be over a quarter of the enlarged direct
  sleeve.
- It adds to **Industrials, already ACT at 50.89%**, and it exceeds the entire P3 equity
  remainder after gold (~8,564 SEK).
- It diversifies country only.

**FINAL CALL: HOLD-WATCH.** The merit is real. The resolution is a correct fit outcome,
not a hedge: one indivisible share is too large and lands in the wrong sector.

**HORIZON:** Medium

### 3c. Other SELL recommendations on current holdings, and standing calls

You get a direct answer to "should I sell anything" every sweep. Beyond ABB.ST (#1):

- **VOLV-B.ST: Defensive SELL at 4, declined. NO ACTION.**
  - Growth (6) and Valuation (5) call it a BUY on the same week's data: revenue +8.0%,
    forward −29% vs trailing.
  - `thesis-review` recommends moving the stored status from TOO_EARLY to INTACT. I agree,
    since the expected driver is now visible in the data.
  - Leverage (D/E 140.9) stays the named watch item.
- **SHB-A.ST: Growth SELL at 3, overruled by #2.**
- **ATCO-B.ST, ALFA.ST, INVE-A.ST, AZN.ST, Avanza Global, Avanza Auto 3, Xetra-Gold,
  BTC0E.AS, ETH: no sell flag.**
  - ALFA prints tomorrow; nothing is decided on it before then.
  - INVE-A.ST's durable hold (D-b) is unchanged.
  - ETH cannot be sold cleanly while P1 is open.
  - Crypto sizing is D-c, not a thesis sell.

**Standing BUY, not re-ranked: AZN.ST, 1 share (Chairman conviction 6, unchanged).**
- Four voices support it on independent fields: Defensive 7, Valuation 6, Macro 6,
  Copycat 4.
- `thesis-review`: INTACT, would buy YES.
- It is not in the Top 5 only because nothing changed. It prints **10-30**, inside the
  collision window (§8).
- **Fit: bought alone, one share takes Healthcare/UK from 42.41% to ~45.3% of the direct
  sleeve (15,421.50 / 34,036.30, my arithmetic). That crosses the 45% line.** Bought
  within the full queue, it ends ~41.2%.
- `portfolio`'s "marginal effect minor" is true in SEK, not in sleeve share. Execute it
  with the queue, not alone.

**Considered for the Top 5, not placed:**
- **V** (Fundamental 8). At 100% of range after +3.6%; Valuation's price objection is
  unanswered.
- **APP** (Growth 5, Contrarian 4). Rank 1 for 10 of 10 runs, now at 1% of range. Price
  and estimates disagree, and S29 still hides the drawdown's size. Watch the next print.
- **FSLR** (Valuation 5, Contrarian 5). Second run holding its forward/FCF pattern. The
  10-19 bar was "a second and third run", so it is one run short. HOLD-WATCH.
- **ATCO-B.ST** (Fundamental 7, Copycat 5). The strongest merit case for *adding* to a
  holding. The fit is the opposite (Industrials ACT). Hold, do not add.
- **WIHL.ST** (first-seen). No voice picked it. It is discovery working: surfaced,
  examined, declined on leverage.

---

## 4. Portfolio health scorecard

Carried verbatim from this sweep's `portfolio` lens:

| Dimension | Rating | Number |
|---|---|---|
| Asset allocation vs targets | WATCH | Equity 72.46% vs 80% (-7.54pp); Cash 12.01% vs 5% (+7.01pp); Gold 2.54% vs 5% (-2.46pp); FI 2.90% vs 0% (+2.90pp, Auto3's own bond/alt sleeve); Crypto 10.09% vs 10% (on target). Four of five classes drift in the same two directions simultaneously; both root causes (PayPal unconverted P3, gold tranche 2 unexecuted) already tracked P-items, not new. |
| Equity sector concentration | ACT | Industrials = 50.89% of direct stock sleeve (VOLV-B+ATCO-B+ALFA+ABB = 16,450.6 SEK of 32,322.8 SEK) — above 45% ACT line. Healthcare (AZN) 42.41% WATCH. Financial Services 6.70% OK. |
| Geography/home bias | ACT | Sweden 47.37% of direct stock sleeve — above 45% ACT line. UK (AZN) 42.41% WATCH. Switzerland (ABB) 10.22% OK. Avanza Global/Auto3 country mix unknown (no look-through, named gap). |
| Currency exposure (revenue) | UNKNOWN | Snapshot has listing currency only, not revenue-by-geography — cannot compute, not guessed. |
| Single-position concentration | WATCH | Avanza Global = 119,999 SEK = 53.66% of total — breaches 15% cap on a literal reading, but it's an internally diversified global index fund, not single-company risk. Largest individual stock AZN at 6.13% — fine. |
| Institution concentration | ACT | Avanza (avanza-isk) = 186,078.45 SEK = 83.20% of total — above 80% cap. All equity/fund/crypto-certificate/gold-ETC capital at one broker. |
| Fee drag | OK | ~187.12 SEK/yr = 0.084% of total, well under 0.4% cap. No holding exceeds 0.5%/yr. CLAUDE.md's priority-2 fee lever reads as FULLY closed now, not "substantially" — the one remaining item it names (2.5% COIN-XBT.ST) was sold 2026-08-17. |
| Wrapper efficiency | OK (one caveat) | ISK total 186,078.45 SEK, comfortably under ~300k allowance (verify current threshold). AF (SEB) empty except immaterial frozen residual. Caveat: ~14,652 SEK PayPal cash outside any wrapper, 12th-plus sweep unexecuted (P3). |
| Drawdown-tolerance fit | UNKNOWN | Per S26, not re-verified this sweep: no backtest file on disk; the one figure ever quoted (-20.62%) has no traceable backing file and its window's own worst equity shock was only -19.14% — never actually tested a -30%-scale shock. |

Total capital (from `portfolio`): **~223,644 SEK**, excluding Revolut and the frozen SEB
fund by design. FX dated 2026-10-16.

**Provisional, per `investor_profile.json` (read this session):**
- `horizon.primary_goal` is "nature UNCERTAIN", with a 3–7y SOFT horizon.
- `constraints.exclusions` is `[]` ("None stated yet").
- `reference_targets` reads 85/10/0/5 with no `gold_pct` (S35).
- `max_drawdown_tolerance_pct` −30 has never been tested against a real shock (S26).

**Proposed reference-target allocation (a labelled proposal from `portfolio`, not a file
write): Equity 80 / Crypto 10 / FI 0 / Cash 5 / Gold 5.**
- This is identical to `portfolio.json.targets`. Writing it into
  `investor_profile.json.reference_targets` closes S35.
- That write needs your approval. No agent makes it.
- The −30% tolerance it is meant to respect remains unverified (S26).

---

## 5. Headline calls

Each needs a decision this session.

1. **SELL all 4 ABB.ST (~3,302.40 SEK) and buy 13 VICI (~3,097.28 SEK) with the proceeds.**
   - This is a fresh, low-confidence decision. The confirmed-Q3 condition was never met.
   - If you want the Q3 report read first (`pdf` skill), that is the one check that could
     withdraw it.
2. **Execute P3 (PayPal → SEK → ISK), unexecuted for a 12th-plus sweep.** ~14,066 SEK net
   after the accepted ~586 SEK spread (`portfolio`). In order:
   - gold tranche 2: ~5,502
   - AZN: 1 share, 1,713.50
   - NVDA: 1 share, 2,104.89
   - SHB: 10 shares, 1,477.00
   - The remainder, ~3,268, goes to Avanza Global.

   If ABB is *not* sold, 15 VICI (3,573.78) slots in ahead of SHB, and SHB shrinks to 7
   shares (my arithmetic).
3. **BUY 10 SHB-A.ST, last in the queue.** This is the insider cluster. Sequence it after
   the non-Swedish buys, or it worsens an ACT country line.
4. **D-c: read the live Avanza value of your 150 BTC0E.AS units.** This is the third
   sweep with no certificate price. The trim trigger is now **~14,577 SEK** (§6).

---

## 6. Open actions vs open decisions

### Open actions (things to go do), by ID

| ID | Status | Action |
|---|---|---|
| **P3** | decided — pending execution (12th-plus sweep) | Convert 1,177.49 USD + 266.88 EUR (~14,652.42 SEK per `portfolio`) inside PayPal and move it to the ISK. Then zero the paypal holdings in `portfolio.json`. |
| **P1** | blocked (on you) | ETH cost basis. Blocks any ETH sale or K4 figure. |
| **P9** | open | Delete the phantom AZN OPENING row in the Excel Transactions tab. |
| **P10** | open | Confirm one 5,000 SEK deposit or two (2026-08-17 vs 2026-08-22). |
| **S35** | open — needs your approval | Write 80/10/0/5 + `gold_pct: 5` into `investor_profile.json.reference_targets`, or replace it with a pointer to `portfolio.json.targets`. |
| **S27** | open — outside this repo | Re-sync the scheduled prompt with CLAUDE.md's flow (scout included), and remove the two stale premises. The bitcoin-fetch narrowing is fixed this sweep. |
| **S26** | open | Run a shock-window backtest into `data/backtests/`. |
| — | record update | VOLV-B.ST `thesis_status` TOO_EARLY → INTACT (`thesis-review`, Chairman concurs). ABB.ST: log that the retest failed for a **data** reason. |

### Open decisions (forks), by ID

The D-series still has no standalone register (S30 is closed). It is reconstructed here.

**D-a — ABB.ST and its proceeds.** Chairman pick: Option 1.
- *Option 1 — sell now, 13 VICI.* Trade-off: you act on unconfirmed Q3 data, and Sweden
  stays ACT until the rest of the queue lands.
- *Option 2 — read the Q3 report first, then sell or hold.* Trade-off: about ten
  minutes of your time, and the risk that this slides into a twelfth undecided week.
- *Option 3 — sell to cash.* Trade-off: Sweden rises to ~52.8% and cash is already 7pp
  over target. Rule this one out.

**D-b — Investor A's unmeasurable valuation.** Durable hold, unchanged.
- No NAV figure exists in `INVE-A.ST.json`.
- The insider rows are mostly a share-class switch (§3a Copycat), not new evidence.
- *Option 1 — keep the hold* (default). Trade-off: a 2,016.50 SEK position with no
  valuation test.
- *Option 2 — record NAV from Investor's Q3 report.* Trade-off: ~10 minutes, for a 0.9%
  position.
- **Pick: Option 1.**

**D-c — crypto sleeve sizing. Escalated: the third sweep with no BTC0E.AS price.**
- **Today's band**, on your pinned full-portfolio convention (`definitions.json`):
  - crypto is 10.09% at the stale BTC mark (`portfolio`)
  - the 11.5% trim fires only if the 150 units exceed **~14,577 SEK** (≈97.2 SEK/unit;
    my arithmetic: 11,549.51 + V > 0.115 × (212,613 + V))
  - the trigger moved up from ~14,080 because ETH fell
- **Partial fix:** a Bitcoin spot price was fetched this sweep. But no file this session
  holds BTC's price at the 08-21 certificate mark, so spot cannot be turned into a
  certificate value.
- Directionally (BTC −4.5% over 30 days, ETH −13.6%), nothing points at the trigger.
  Direction is not a mark.
- *Option 1 — you read the Avanza value (one minute).* Trade-off: none worth naming.
  From next sweep, each week's BTC spot then gives a directional anchor.
- *Option 2 — wait for a feed.* Trade-off: a fourth unsizable sweep. The certificate has
  404'd for three straight sweeps, so a feed is not coming by itself.
- *Option 3 — record today's Avanza value as the new mark, and scale it weekly by
  CoinGecko spot.* Trade-off: a proxy, not a price. Tracking error is small for a 0%-fee
  physically-backed note.
- **Pick: Option 1 now, then Option 3 as the standing method.**

### Structural decisions (non-stock)

Levers 1–2 (wrapper, fees) are closed and not re-flagged. `portfolio` reads the fee lever
as fully closed (P4 closed 2026-08-17). CLAUDE.md's "substantially done" wording is
stale (§9).

**ACTION:** Execute P3. Recommended; this system trades nothing.
- **POSITION:** ~14,652.42 SEK in PayPal (1,177.49 USD → 11,679.41 SEK; 266.88 EUR →
  2,973.01 SEK at this sweep's FX, per `portfolio`), outside any wrapper.
- **TARGET:** the ISK, split per §5 call 2. Gold tranche 2 (~5,502 SEK) closes the
  −2.46pp gold gap in full via the already-cleared Xetra-Gold.
- **REASON:** a recurring ~4% spread, plus the binding funding constraint on four BUYs
  and the gold gap.
- **THESIS STATUS:** decided by you 2026-08-17 (Option A).
- **WHAT CHANGED:** only the count. It is now a 12th-plus sweep, and SHB joins the queue.
- **BREAK CONDITION:** a fee-free route appears, or the realised spread is materially
  above 4%.
- **CONFIDENCE:** High (arithmetic, not a forecast).
- **HORIZON:** Long

**ACTION:** Gold tranche 2, ~5,502 SEK of Xetra-Gold (DE000A0S9GB0), first call on P3.
- **POSITION:** 5,689.22 SEK at cost (2.54%). No live price.
- **TARGET:** 5% (`portfolio.json.targets`), ceiling 7.5%.
- **REASON:** `macro-regime` names gold as the instrument this regime rewards, two rate
  decisions out. `thesis-review`: TOO_EARLY, would buy YES.
- **THESIS STATUS:** TOO_EARLY (structural crash hedge).
- **WHAT CHANGED:** nothing. It is funding-bound.
- **BREAK CONDITION:** S26's shock-window result shows gold adds nothing at 5%.
- **CONFIDENCE:** Medium
- **HORIZON:** Long
- *Not in the picks ledger:* no fetched price to join.

---

## 7. Cost of being wrong

| Headline call | If wrong | Realistic SEK downside | Recoverable? |
|---|---|---|---|
| SELL 4 ABB | Q3 confirms a re-rating, ABB +15% | ~495 SEK foregone (15% × 3,302.40) | Yes. It can be rebought tax-free in the ISK. |
| BUY 13 VICI | Hawkish FOMC, REIT −30%, krona +10% | ~929 + ~310 FX, offset by ~240 SEK/yr dividend (7.74%) | Yes, with time. ~1.4% of capital. |
| Execute P3 + queue | Spread is certain; NVDA −40% (beta 2.2), AZN −30%, gold tranche 2 −20% | ~586 spread + ~842 + ~514 + ~1,100 | The spread, no, and it recurs while P3 waits. The positions, yes. |
| BUY 10 SHB | Insiders early, bank −20% | ~295 SEK, offset by ~79 SEK/yr dividend | Yes. 0.66% of capital. |
| D-c: no trim at an unknown mark | The sleeve is above the trigger, then crypto halves | ~11,290 on the 22,580.51 sleeve; only the overweight slice was avoidable | The overweight part, yes. Whether the whole loss fits −30% is S26's untested question. |

All figures are my arithmetic on this sweep's prices and FX.

---

## 8. Timing collisions

From `data/cache/calendar/20261026-events.json`. Caveats:
- `macro_calendar.json` was last verified 2026-08-03.
- US/SE CPI dates are missing.
- The fetch is **holdings-only again**, so VICI, NVDA, APP and FIX have no dates.

- **The four industrial print dates came back already past** (ABB 10-20, SHB 10-21, ATCO
  10-22, VOLV 10-23). The source is stale for these names. ABB's next print is unknown.
  Selling ABB now collides with no known event.
- **10-27: ALFA.ST reports, on FOMC day 1.** No ALFA action is proposed. Read the
  results, not the day-one move.
- **10-27/28: FOMC.** Inside the window for **VICI and NVDA** (both USD) and for the
  crypto sleeve. Buying before means owning the statement; buying after means paying
  whatever it sets. Neither is an edge this system has. Execute when funded; do not
  time it.
- **10-30: AZN.ST reports.** If P3 lands first, the AZN share is bought into the print.
  That is a conscious choice, acceptable at a Medium horizon.
- **11-04: Riksbank decision** (7 trading days out). It is relevant to SHB (both
  directions) and to any Swedish property name. The SHB buy, last in the queue, may land
  near it.

---

## 9. Data gaps for `meta`

Ordered by what each cost this sweep. Surfaced, not fixed.

1. **No ABB Q3 confirmation, and the earnings source returned past dates for four
   holdings.** A pre-committed Chairman test could not run as designed. Sourcing the
   report via the `pdf` skill is the workaround. The calendar source itself is stale.
2. **BTC0E.AS has no price for a third sweep.** The bitcoin spot fix held (S27 finding
   3), but D-c still cannot be evaluated without an anchor mark (§6).
3. **The calendar is holdings-only for a fifth sweep, and it now costs a live decision.**
   VICI, a Top-5 BUY, has no earnings date inside FOMC week. The 2026-09-28 "considered"
   note said to open an item "on the next sweep where a live candidate's earnings date gap
   is shown to matter, without further deliberation". This is that sweep.
4. **FI data-cleaning gaps.** The issuer-name search returned an Avtech Sweden row under
   Handelsbanken, and two trades appear twice (History/Revised). Hvied's two rows
   disagree on price (158.13 vs 185.13). Raw counts overstate clusters unless rows are
   de-duplicated and filtered by ISIN.
5. **FI scope is still holdings-only.** WIHL.ST, CATE.ST, DIOS.ST and AZA.ST have no
   insider read, so Copycat adds nothing to discovery. The names needed: "Wihlborgs
   Fastigheter", "Catena", "Diös Fastigheter", "Avanza Bank Holding", in exact Swedish
   spelling.
6. **INVE-A.ST `revenue_growth` −60.8% is unflagged for a second sweep.** It was reported
   as new; it is not. Its root cause is contested (USD/SEK vs holding-company
   revenue definition).
7. **S29 has fresh forcing evidence.** APP sits at 1% of range, rank 1 for 10 of 10 runs.
   Growth and Contrarian both capped it because the drawdown's size is invisible.
8. **S32 persists.** AZN/ABB FCF yields are still unit-mismatched; TSM 55.43% is still
   unflagged.
9. **S21:** AZN.ST `forward_pe` is missing in 10 of 10 runs.
10. **The macro block runs at two speeds.** Fed funds and US CPI are 55 days stale going
    into an FOMC; FX is 10 days old.
11. **Lens-level slips caught here:**
    - `macro-regime`'s "firming dollar" was week-on-week wrong.
    - `valuation`'s "REVIVED" read 5.53% as inside a 4–5% band.
    - The orchestrator's Investor "fresh buying" was mostly a share-class switch.
    - `portfolio`'s "marginal effect minor" on one AZN share understates its effect on
      the sleeve share.
    - CLAUDE.md's "fee lever substantially done" is stale (P4 closed).
12. **Still missing everywhere:** EV/EBITDA, FFO/AFFO (VICI), backlog (FIX), bank
    NIM/credit metrics (SHB), policy data (FSLR), commodity and credit-spread series.

---

## 10. Learning notes

- **A two-sided test can come back "neither".** ABB's pre-committed test had a retire
  side and a revive side. On the numbers, both failed narrowly. Calling that "revived"
  would have dressed a judgement up as a rule. The honest output is: the rule was
  inconclusive, so here is the judgement, at low confidence.
- **Insider buying right after a report is normal timing. What makes it a signal is
  breadth and size.** Swedish insiders can only trade in open windows, which usually
  follow a report. So "they bought after the print" is not the point. Four people at
  three levels of the company each putting in real money, on top of an August cluster,
  is. The same register also showed why rows have to be cleaned first: a duplicate, a
  different company, and a share-class switch were all sitting in the raw data.
- **"The dollar is firming" depends on the comparison window.** Against August, yes;
  against last week, no. A regime claim needs its window stated, or it reads as news
  when it is old.
- **One share can be a concentration problem.** FIX has the cleanest growth fields in
  the file. But its smallest possible position is ~12,690 SEK, more than the whole free
  equity budget, in the sector you are already overweight. A good idea that cannot be
  sized sensibly is a WATCH, not a BUY.

---

`journal` **must run next.** An unlogged memo is invisible to the next session and can
never be reconciled. Then run `python scripts/decisions.py record --picks
data/picks/2026-10-26-picks.csv`, followed by `python scripts/decisions.py basis --write`.
